Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most-advanced program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis’ second pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung and other solid tumors. Aktis has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis’ proprietary pipeline. The Drug Metabolism and Pharmacokinetics (DMPK) group is recruiting a Scientist/Senior Scientist to support our miniprotein-based radioconjugate discovery programs. The successful candidate will play a key role in advancing our understanding of proteolytic stability and pharmacokinetic profiling in preclinical species. Primary responsibilities include bioanalytical method development, qualification, and implementation, as well as design, execution, and interpretation of preclinical pharmacokinetic studies. In addition, the Scientist/Senior Scientist will serve as the DMPK representative on cross-functional program teams, contributing scientific expertise to drive program progression.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Education Level
Ph.D. or professional degree